AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31656181 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression score and food insecurity
Number of subjects: 3350
Study 31656181 — intervention group
Group type: EXPERIMENTAL
Intervention: Family type (nuclear vs. joint)
Number of subjects: 3350
Study 31656181 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression score, type of toilet, garbage disposal, household food insecurity, sex
Number of subjects: 3350
Study 31656181 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression score, type of toilet, garbage disposal, household food insecurity, sex, perceived overall physical condition of the infant after birth
Number of subjects: 3350
Study 29924056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (5 mg)
Number of subjects: 181
Study 29924056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 26667245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline body fat mass (FM)
Number of subjects: 633
Study 26667245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IGF-1
Number of subjects: 633
Study 26667245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline osteocalcin
Number of subjects: 633
Study 26667245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ghrelin
Number of subjects: 633
Study 26667245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leptin
Number of subjects: 633
Study 25099540 — intervention group
Group type: EXPERIMENTAL
Intervention: HOS + fish oil (FO; 5 g EPA and DHA)
Number of subjects: 16
Study 25099540 — intervention group
Group type: EXPERIMENTAL
Intervention: HOS + algal oil (AO; 5 g DHA)
Number of subjects: 16
Study 25099540 — intervention group
Group type: EXPERIMENTAL
Intervention: high-linoleic acid sunflower oil (HLS)
Number of subjects: 16
Study 25099540 — intervention group
Group type: COMPARATOR
Intervention: high-oleic acid sunflower oil (HOS; control)
Number of subjects: 16
Study 22928960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring intervention (pairing new reviewers with senior reviewers for first three manuscript reviews)
Number of subjects: 46
Study 22928960 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard written informational materials)
Number of subjects: 46
Study 22928960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring intervention
Number of subjects: 46
Study 22928960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 20101008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate ketogenic diet (LCKD)
Number of subjects: 146
Study 20101008 — intervention group
Group type: COMPARATOR
Intervention: Orlistat therapy plus low-fat diet (O + LFD)
Number of subjects: 146
Study 17405805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention and informative brochure
Number of subjects: 200
Study 17405805 — intervention group
Group type: COMPARATOR
Intervention: Informative brochure only
Number of subjects: 200
Study 15867009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone enanthate (100 mg weekly) plus oral levonorgestrel (31.25 microg daily)
Number of subjects: 41
Study 15867009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone enanthate (100 mg weekly) plus oral levonorgestrel (62.5 microg daily)
Number of subjects: 41
Study 12410751 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (2250 mg intramuscular) twice daily for 2 days
Number of subjects: 138
Study 12410751 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg orally) twice daily for 7 days
Number of subjects: 138
Study 11551252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucocorticoid beclomethasone (BDP; 400 microg/day)
Number of subjects: 16
Study 11551252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11551252 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=5)
Number of subjects: 16
Study 9131473 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark system (Brå)
Number of subjects: 60
Study 9131473 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ-system
Number of subjects: 60
Study 7703829 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 10
Study 2887100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 16027
Study 2887100 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16027
Study 30066325 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention group (n = 73)
Number of subjects: 145
Study 27001985 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat in combination with bortezomib and dexamethasone
Number of subjects: 0
Study 27001985 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with bortezomib and dexamethasone
Number of subjects: 0
Study 25897293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative cell salvage (CS)
Number of subjects: 150
Study 25897293 — intervention group
Group type: COMPARATOR
Intervention: Control group (without intra-operative CS)
Number of subjects: 150
Study 23084272 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving the PD stent in place for 7 to 10 days (stent group)
Number of subjects: 151
Study 23084272 — intervention group
Group type: COMPARATOR
Intervention: Immediate removal of the PD stent after the procedure (stent removed group)
Number of subjects: 151
Study 23084272 — intervention group
Group type: COMPARATOR
Intervention: No stent (no stent group)
Number of subjects: 151
Study 20493653 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Element
Number of subjects: 1262
Study 20493653 — intervention group
Group type: COMPARATOR
Intervention: TAXUS Express
Number of subjects: 1262
Study 18534127 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 13
Study 16154181 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor 1 g/day for 3 months (n=37)
Number of subjects: 77
Study 16154181 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n=40)
Number of subjects: 77
Study 12813118 — intervention group
Group type: EXPERIMENTAL
Intervention: Active AMPT (five 1-g doses administered orally over 28 hours)
Number of subjects: 18
Study 12813118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diphenhydramine hydrochloride, five 50-mg doses administered similarly)
Number of subjects: 18
Study 10872756 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 487
Study 10872756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 10872756 — intervention group
Group type: COMPARATOR
Intervention: Lower dose control group
Number of subjects: 487
Study 10872756 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose group
Number of subjects: 487
Study 8686101 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 60
Study 8686101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60
Study 8686101 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 60
Study 1899636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral streptokinase-streptodornase (SS), dosage: two tablets three times a day for eight days
Number of subjects: 190
Study 1899636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 30411802 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal cytology
Number of subjects: 0
Study 30411802 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (HR-HPV) positivity
Number of subjects: 0
Study 30411802 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-testing HR-HPV+ with and without abnormal cytology
Number of subjects: 0
Study 30411802 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16+
Number of subjects: 0
Study 30411802 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18+
Number of subjects: 0
Study 28692476 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 250
Study 28692476 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastric banding
Number of subjects: 250
Study 28692476 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 250
Study 28692476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 26874901 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg per day
Number of subjects: 2840
Study 26874901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2840
Study 24617818 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (NSAID)
Number of subjects: 80
Study 24617818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22104040 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at 15 Hz above cramp threshold frequency (TF)
Number of subjects: 20
Study 22104040 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at 20 Hz above cramp threshold frequency (TF)
Number of subjects: 20
Study 22104040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cramp threshold frequency (TF)
Number of subjects: 20
Study 19932946 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chest wall radiotherapy (PMRT)
Number of subjects: 0
Study 19932946 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 0
Study 18236178 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight bearing (P)
Number of subjects: 43
Study 18236178 — intervention group
Group type: EXPERIMENTAL
Intervention: Full weight bearing (F)
Number of subjects: 43
Study 15791442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (group A, n=25)
Number of subjects: 58
Study 15791442 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (group B, n=25)
Number of subjects: 58
Study 12472909 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg day-1
Number of subjects: 24
Study 12472909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9862577 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of truncated hHb1 hair keratin in breast carcinomas
Number of subjects: 0
Study 9862577 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study of hHb1 expression
Number of subjects: 0
Study 7897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward and response costs
Number of subjects: 36
Study 7897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Response costs only
Number of subjects: 36
Study 7897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward only
Number of subjects: 36
Study 7897047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 1699985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmalgen
Number of subjects: 80
Study 1699985 — intervention group
Group type: EXPERIMENTAL
Intervention: Allpyral
Number of subjects: 80
Study 1699985 — intervention group
Group type: COMPARATOR
Intervention: Histamine chloride (placebo)
Number of subjects: 80
Study 580285 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol, administered orally, once weekly
Number of subjects: 0
Study 580285 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 0
Study 31586203 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased miR-203 levels in ovarian cancer patients
Number of subjects: 225
Study 31586203 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-203 expression
Number of subjects: 225
Study 31586203 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of miR-203 levels with established disease prognostic markers
Number of subjects: 225
Study 30196481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual focus (DF) MiSight® contact lenses (CLs)
Number of subjects: 74
Study 30196481 — intervention group
Group type: COMPARATOR
Intervention: Single-vision (SV) spectacles
Number of subjects: 74
Study 28401849 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 125
Study 28401849 — intervention group
Group type: COMPARATOR
Intervention: Enhanced community standard control group
Number of subjects: 125
Study 26115467 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 408
Study 26115467 — intervention group
Group type: COMPARATOR
Intervention: Endovascular coiling
Number of subjects: 408
Study 23748114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg every 4 weeks (Q4wk)
Number of subjects: 466
Study 23748114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 6 mg every 8 weeks (Q8wk)
Number of subjects: 466
Study 23748114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 10 mg every 8 weeks (Q8wk)
Number of subjects: 466
Study 23748114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab (various doses)
Number of subjects: 466
Study 23748114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 21199488 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn to think (LTT) curriculum, one activity every 2 weeks for 4 school years
Number of subjects: 166
Study 21199488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study 19478622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg body weight of gadobenate dimeglumine (Gd‐BOPTA)
Number of subjects: 20
Study 19478622 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg body weight of gadopentetate dimeglumine (Gd‐DTPA)
Number of subjects: 20
Study 17227809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (DG)
Number of subjects: 6
Study 17227809 — intervention group
Group type: COMPARATOR
Intervention: Vaginal micronized progesterone
Number of subjects: 6
Study 15287372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise during euglycemic insulin clamp
Number of subjects: 12
Study 15287372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise during hyperglycemic insulin clamp
Number of subjects: 12
Study 11706668 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 300 mg per day for 12 days
Number of subjects: 98
Study 11706668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 11706668 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC
Number of subjects: 98
Study 9152515 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenized yeast tablet (200 micrograms daily for 4 years)
Number of subjects: 226
Study 9152515 — intervention group
Group type: COMPARATOR
Intervention: Placebo yeast tablet (identical to Se tablet)
Number of subjects: 226
Study 9152515 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenized table salt (supplemented)
Number of subjects: 226
Study 9152515 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of Se treatment
Number of subjects: 226
Study 9152515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of Se treatment
Number of subjects: 226
Study 8265093 — intervention group
Group type: EXPERIMENTAL
Intervention: EAP-1 (doxorubicin 20 mg/m2 on days 1 and 7, cisplatin 40 mg/m2 on days 2 and 8, etoposide 120 mg/m2 on days 4-6)
Number of subjects: 63
Study 8265093 — intervention group
Group type: EXPERIMENTAL
Intervention: EAP-2 (doxorubicin 40 mg/m2 on day 1, cisplatin 80 mg/m2 in 3 divided doses on days 1-3, etoposide 100 mg/m2 on days 1-3)
Number of subjects: 63
Study 3312216 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 21
Study 3312216 — intervention group
Group type: COMPARATOR
Intervention: Scarlet red
Number of subjects: 21
Study 31385178 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose nicorandil (30 mg/day)
Number of subjects: 330
Study 31385178 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-dose nicorandil (15 mg/day)
Number of subjects: 330
Study 31385178 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 330
Study 27911566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-directed step targets during pulmonary rehabilitation (PR) for 8 weeks
Number of subjects: 152
Study 27911566 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (PR comprising 8 weeks, two supervised sessions per week)
Number of subjects: 152
Study 25875256 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 12 weeks
Number of subjects: 111
Study 25875256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 25875256 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 111
Study 23573993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent cap‐assisted esophagogastroduodenoscopy
Number of subjects: 70
Study 23573993 — intervention group
Group type: COMPARATOR
Intervention: Conventional esophagogastroduodenoscopy
Number of subjects: 70
Study 21246232 — intervention group
Group type: EXPERIMENTAL
Intervention: AV/pN-gapA (GAPDH-display strain)
Number of subjects: 0
Study 19947068 — intervention group
Group type: COMPARATOR
Intervention: Tramadol alone
Number of subjects: 133
Study 19947068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus remifentanil
Number of subjects: 133
Study 19947068 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 133
Study 19947068 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus remifentanil
Number of subjects: 133
Study 16107490 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent acute otitis media
Number of subjects: 210
Study 16107490 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent middle ear effusion
Number of subjects: 210
Study 15335150 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-locating catheter
Number of subjects: 1000
Study 15335150 — intervention group
Group type: COMPARATOR
Intervention: Classic Tenckhoff catheter
Number of subjects: 1000
Study 11496616 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine/propofol (0.33-1.0 mg/kg BW/h (S)-ketamine + 1-3 mg/kg BW/h propofol)
Number of subjects: 30
Study 11496616 — intervention group
Group type: COMPARATOR
Intervention: (S)-ketamine/midazolam (0.33-1.0 mg/kg BW/h (S)-ketamine + 0.033-0.1 mg/kg BW/h midazolam)
Number of subjects: 30
Study 11496616 — intervention group
Group type: COMPARATOR
Intervention: (S)-ketamine/midazolam
Number of subjects: 30
Study 11496616 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine/propofol
Number of subjects: 30
Study 11496616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 30
Study 9930476 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 32
Study 9930476 — intervention group
Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 32
Study 9930476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Centrifugal and Roller pumps)
Number of subjects: 32
Study 8061102 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus cytarabine (MTT+Ara‐C)
Number of subjects: 143
Study 8061102 — intervention group
Group type: COMPARATOR
Intervention: Daunomycin plus cytarabine (DNM+Ara‐C)
Number of subjects: 143
Study 8061102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 143
Study 2845348 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐polymyxin B (TP)
Number of subjects: 158
Study 2845348 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin sulfate (GS)
Number of subjects: 158
Study 2845348 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium sulfacetamide (SS)
Number of subjects: 158
Study 31808376 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Teamwork program
Number of subjects: 162
Study 31808376 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 162
Study 30541492 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE; maximum of 16 sessions in 16 weeks)
Number of subjects: 150
Study 30541492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Prolonged Exposure (iPE; maximum of 12 sessions in four weeks and two booster sessions)
Number of subjects: 150
Study 30541492 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-based Treatment (PBT; maximum of eight sessions skills training followed by eight sessions PE in 16 weeks)
Number of subjects: 150
Study 30541492 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 150
Study 27353492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU/day)
Number of subjects: 65
Study 27353492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26182736 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule Tamsulosin 0.4 mg, 1 daily up to 4 weeks
Number of subjects: 100
Study 26182736 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 Capsule daily up to 4 weeks
Number of subjects: 100
Study 23890458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby music played via headphones at a volume of 50‐60 dB
Number of subjects: 90
Study 23890458 — intervention group
Group type: COMPARATOR
Intervention: Silence (headphones placed on infants' ears with no music played)
Number of subjects: 90
Study 20451698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive caffeine history screening
Number of subjects: 194
Study 20451698 — intervention group
Group type: COMPARATOR
Intervention: Routine caffeine history screening
Number of subjects: 194
Study 20451698 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable serum caffeine
Number of subjects: 194
Study 18187607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 11
Study 18187607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17006068 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 12
Study 17006068 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 12
Study 12701015 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time magnetic endoscope imaging (MEI)
Number of subjects: 71
Study 12701015 — intervention group
Group type: COMPARATOR
Intervention: No MEI view (Control)
Number of subjects: 71